Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-1387 + Entecavir in Chronic Hepatitis B
NCT04568265Phase 2Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Jun 2020
- Primary completion
- Oct 2022
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dasminapant in Chronic Hepatitis B (CHB) (4 arms), sponsored by Ascentage Pharma. Primary endpoints: Dose-limiting toxicity rate at 28 days and Decline in Hepatitis B surface Antigen at 12 weeks. Started Jun 2020; status: recruiting.
02
Drugs
dasminapant
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04568265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04568265.